http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
유방암 수술 결정을 위한 수술 전 자기공명영상의 임상적 의의
박우찬 한국유방암학회 2006 Journal of breast cancer Vol.9 No.4
Purpose: Currently MRI (Magnetic Resonance Imaging) is widely used for the preoperative staging of breast cancer. In this study, we assessed the impact of preoperative breast MRI on the surgical management of breast cancer in women. Methods: From March 2004 to October 2006, 162 cases were enrolled for preoperative MRI for the staging of breast cancer. The MRI findings and clinicopathological results were investigated and the accuracy of breast MRI was analyzed with respect to the detection of multiplicity, nipple involvement and bilaterality of the breast cancers. Results: For detecting multifocal lesions, the sensitivity and specificity of breast MRI were 100% and 48.5%, respectively, and the results of bresat ultrasound were 100% and 63.4%, respectively. For detecting nipple invasion, the sensitivity and specificity of breast MRI was 80% and 74.6%, and for ultrasound was 33.3% and 86.4%. In 27 cases (16.7%) the type of surgery was changed according to the preoperative MRI findings; however, in only 6 cases were the MRI findings in concordance with the pathological findings of the mastectomy specimen. Conclusion: In clinical application of breast MRI for preoperative staging, the decision to undertake surgery for breast cancer based on a MRI findings should be prudent due to its low specificity.
동적 장면을 지원하는 효율적인 광선 추적 하드웨어에 대한 FPGA상에서의 구현
박우찬,이진영,김정길 한국반도체디스플레이기술학회 2022 반도체디스플레이기술학회지 Vol.21 No.4
In this paper, our ray tracing hardware is implemented on the latest high-capacity FPGA board. The system included ray tracing hardware for rendering and tree building hardware for handling dynamic scenes. The FPGA board used in the implementation is a Xilinx Alveo U250 accelerator card for data centers. This included 12 ray tracing hardware cores and 1 tree-building hardware core. As a result of testing in various scenes in Full HD resolution, the FPS performance of the proposed ray tracing system was measured from 8 to 28. The overall average is about 17.7 FPS.
버거씨병 환자에서 발생한 상장간막 정맥 혈전증: 컴퓨터 단층 촬영에 의한 진단
박우찬,박장상,고용복 대한혈관외과학회 1991 Vascular Specialist International Vol.7 No.1
Superior mesenteric venous thrombosis (SMVT) is an unusual disease. Making diagnosis and adequate treatment are usually difficult because its symptoms and signs, laboratory or radiologic findings are not specific. Diagnosis of SMVT by contrast-enhanced computed tomography was estabilished by Rosen in 1984 with the folloving criteria: (1) enlargement of mesenteric or portal vein, (2) sharp definition of venous wall, (3) hyperlucency of venous wall, (4) central veus low density(thrombus). Contrast-enhanced CT provides us the most accurate information in making diagnosis of SMVT. Immediate operation followed by postoperative anticoagulation therapy and 2nd look procedure is known to improve the survival of SMVT. The authors experienced a case of superior mesenteric venous thrombosis in the patient with previously known Buergers disease who was diagnosed by contrast-enhanced CT and treated by 2 operations and anticoagulation therapy with good recovery. We report this case with review of literatures.
박우찬,방주희,남아롱,JINMEIHUA,서혜림,김재민,오경석,김태용,오도연 대한암학회 2021 Cancer Research and Treatment Vol.53 No.1
Purpose The soluble form programmed death-ligand 1 (sPDL1) has immunosuppressive properties and is being studied as a candidate biomarker for immuno-oncology drug development. We measured the serum sPDL1 at pre-and post-chemotherapy and evaluated its prognostic implication and dynamics during chemotherapy in advanced gastric cancer (GC). Materials and Methods We prospectively enrolled 68 GC patients who were candidates for palliative standard first-line chemotherapy, and serially collected blood at baseline and after one cycle of chemotherapy, at the best response and after disease progression. sPDL1 was measured using an enzyme-linked immunosorbent assay. Response to chemotherapy, overall survival (OS), progression-free survival (PFS) and other prognostic factors including neutrophil-lymphocyte ratio (NLR) were obtained. The cut-off value of sPDL1 levels for survival analysis was found using C-statistics. Results The median baseline sPDL1 was 0.8 ng/mL (range, 0.06 to 6.06 ng/mL). The median OS and PFS were 14.9 months and 8.0 months, respectively. sPDL1 and NLR showed a weak positive correlation (Spearman’s rho=0.301, p=0.013). Patients with low levels of sPDL1 at diagnosis (< 1.92 ng/mL) showed a better OS and PFS than patients with a high sPDL1. The baseline sPDL1 before treatment was higher in the progressive disease group than in the stable disease and partial response groups. Patients whose sPDL1 increased after the first cycle of chemotherapy showed worse PFS and OS. Following disease progression, sPDL1 increased compared with the baseline. Conclusion sPDL1 at prechemotherapy confers a prognostic value for PFS and OS in GC patients under palliative first-line chemotherapy. Dynamics of sPDL1 during chemotherapy correlates with disease progression.